10679-1-AP

antibody from Proteintech Group

Targeting: KLK3 APS, PSA

Provider product page for 10679-1-AP

Western blot

ELISA

Immunohistochemistry

Antibody data

Antibody Data
Antigen structure
References [35]
Comments [0]
Validations
Immunohistochemistry [2]

Submit

Product number: 10679-1-AP - Provider product page
Provider: Proteintech Group
Proper citation: Proteintech Cat#10679-1-AP, RRID:AB_2134244
Product name: KLK3/PSA antibody
Antibody type: Polyclonal
Description: KLK3/PSA antibody (Cat. #10679-1-AP) is a rabbit polyclonal antibody that shows reactivity with human and has been validated for the following applications: IHC, WB,ELISA.
Reactivity: Human
Host: Rabbit
Conjugate: Unconjugated
Isotype: IgG
Vial size: 20ul, 150ul

KLK3 protein structure - 10679-1-AP shown in red.

Submitted references Marine trichodermamide B inhibits prostate cancer progression via catalase inhibition-induced apoptosis.

Fang W, Chen C, Nie M, Liu Q, Huang T, Gao C, Liu Y, Zhou X, Wang X
Cell communication and signaling : CCS 2026 Feb 16;24(1)

Aryl hydrocarbon receptor is critical for both AR-dependent and AR-indifferent enzalutamide resistance in castration-resistant prostate cancer.

Chen CH, Brown R, Vander Griend DJ, Gao AC, Wu BJ
Oncogene 2026 Apr;45(15):1312-1323

Crosstalk between OPG/RANKL/RANK in bone marrow mesenchymal stem cells and Wnt/b-catenin pathway in prostate cancer cells regulates bone metastasis of prostate cancer.

Ye S, Lin Q, Deng M, Huang S, Mao C, Zhang J, Zhan W, Chen G
Polish journal of pathology : official journal of the Polish Society of Pathologists 2025;76(1):25-37

Single-cell and spatial RNA sequencing identify divergent microenvironments and progression signatures in early- versus late-onset prostate cancer.

Cheng Y, Liu B, Xin J, Wu X, Li W, Shang J, Wu J, Zhang Z, Xu B, Du M, Cheng G, Wang M
Nature aging 2025 May;5(5):909-928

Characterization of RNA editing gene APOBEC3C as a candidate tumor suppressor in prostate cancer.

Wang LY, Shi J, Wang MF, Liu YM, Guo HS, Wang JC, Jiang S, Liang JQ, Liao XH, Chen SY
Scientific reports 2025 May 22;15(1):17725

Elevated VRK1 levels after androgen deprivation therapy promote prostate cancer progression by upregulating YAP1 expression.

Meng Y, Ge J, Zhou C, Ma H, Chen C, Zhou Y, Hu X, Xu Y, Wang X, Shi G, Yu W, Zhang J
Journal of cancer research and clinical oncology 2025 Mar 20;151(3):116

ZFHX3 is integral to androgen/AR signaling involving protein association with AR in prostate cancer cells.

Fu X, Zhang Z, Chen R, A J, An N, Tian X, Dong JT
Scientific reports 2025 Jul 1;15(1):20931

Diterpene glycosides from Fructus Rubi ameliorates benign prostatic hyperplasia in rats through the androgen and TGF-β/Smad signaling pathway.

Yu J, Zhang X, Wang J, Cheng K, Yang B, Du J, Chen L, Wu Y, Li Y
Journal of ethnopharmacology 2025 Jan 30;337(Pt 1):118756

A Super-Enhancer-Driven Transcriptional Regulatory Circuit Underlying Abiraterone Resistance in Castration-Resistant Prostate Cancer.

Jiang L, Wang J, Peng G, Zhang H, Fang J, Gao Y, Lou E, Liu Y, Ding W, Liu B, Mao Q, Jiang L, Liu A, Li X, Hu S, Ma Q, Zheng Y, Zhao Z, Shi X
Advanced science (Weinheim, Baden-Wurttemberg, Germany) 2025 Aug;12(31):e01284

Cannabidiol Enhances the Anticancer Activity of Etoposide on Prostate Cancer Cells.

Erzurumlu Y, Catakli D
Cannabis and cannabinoid research 2025 Apr;10(2):258-276

NOSTRIN is involved in benign prostatic hyperplasia via inhibition of proliferation, oxidative stress, and inflammation in prostate epithelial cells.

Li S, Yu C, Xiao H, Xu Q, Gao B, Guo L, Sun Z, Liu J
Translational andrology and urology 2024 Sep 30;13(9):2055-2069

Human intermediate prostate cancer stem cells contribute to the initiation and development of prostate adenocarcinoma.

Mu J, Li R, Zheng Y, Lu Y, Ma L, Yin L, Zhang M, Ma W, Chang M, Liu A, Li J, Zhu H, Wang D
Stem cell research & therapy 2024 Sep 11;15(1):296

Characterization of the Peroxisomal Proteome and Redox Balance in Human Prostate Cancer Cell Lines.

Hussein MAF, Lismont C, Costa CF, Li H, Claessens F, Fransen M
Antioxidants (Basel, Switzerland) 2024 Nov 1;13(11)

CAPN2 promotes apalutamide resistance in metastatic hormone-sensitive prostate cancer by activating protective autophagy.

Qi Z, Bai X, Wu L, Zhang P, Guo Z, Yu Y
Journal of translational medicine 2024 Jun 6;22(1):538

Reciprocal regulation between RACGAP1 and AR contributes to endocrine therapy resistance in prostate cancer.

Wang J, Liu H, Yu Z, Zhou Q, Sun F, Han J, Gao L, Dou B, Zhang H, Fu J, Jia W, Chen W, Hu J, Han B
Cell communication and signaling : CCS 2024 Jun 19;22(1):339

USP54 is a potential therapeutic target in castration-resistant prostate cancer.

Zhou C, Zhang X, Ma H, Zhou Y, Meng Y, Chen C, Shi G, Yu W, Zhang J
BMC urology 2024 Feb 6;24(1):32

Overexpression of RACGAP1 by E2F1 Promotes Neuroendocrine Differentiation of Prostate Cancer by Stabilizing EZH2 Expression.

Song Z, Cao Q, Guo B, Zhao Y, Li X, Lou N, Zhu C, Luo G, Peng S, Li G, Chen K, Wang Y, Ruan H, Guo Y
Aging and disease 2023 Oct 1;14(5):1757-1774

Progesterone regulates the endoplasmic reticulum-associated degradation and Unfolded Protein Response axis by mimicking the androgenic stimulation in prostate cancer cells.

Erzurumlu Y, Dogan HK, Catakli D
Molecular biology reports 2023 Feb;50(2):1253-1265

Quercetin in Tonglong Qibi decoction ameliorates testosterone-induced benign prostatic hyperplasia in rats by regulating Nrf2 signalling pathways and oxidative stress.

Fu W, Chen S, Zhang Z, Chen Y, You X, Li Q
Andrologia 2022 Oct;54(9):e14502

Correction: Expansion of mouse castration-resistant intermediate prostate stem cells in vitro.

Xu Y, Mu J, Zhou Z, Leng Y, Yu Y, Song X, Liu A, Zhu H, Li J, Wang D
Stem cell research & therapy 2022 Nov 25;13(1):522

Expansion of mouse castration-resistant intermediate prostate stem cells in vitro.

Xu Y, Mu J, Zhou Z, Leng Y, Yu Y, Song X, Liu A, Zhu H, Li J, Wang D
Stem cell research & therapy 2022 Jul 15;13(1):299

Prostate cancer cell proliferation is influenced by LDL-cholesterol availability and cholesteryl ester turnover.

Raftopulos NL, Washaya TC, Niederprüm A, Egert A, Hakeem-Sanni MF, Varney B, Aishah A, Georgieva ML, Olsson E, Dos Santos DZ, Nassar ZD, Cochran BJ, Nagarajan SR, Kakani MS, Hastings JF, Croucher DR, Rye KA, Butler LM, Grewal T, Hoy AJ
Cancer & metabolism 2022 Jan 15;10(1):1

α-Terthienyl induces prostate cancer cell death through inhibiting androgen receptor expression.

Gan X, Huang H, Wen J, Liu K, Yang Y, Li X, Fang G, Liu Y, Wang X
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 2022 Aug;152:113266

NCAPD3 promotes prostate cancer progression by up-regulating EZH2 and MALAT1 through STAT3 and E2F1.

Jing Z, Liu Q, Xie W, Wei Y, Liu J, Zhang Y, Zuo W, Lu S, Zhu Q, Liu P
Cellular signalling 2022 Apr;92:110265

RNF8 up-regulates AR/ARV7 action to contribute to advanced prostate cancer progression.

Zhou T, Wang S, Song X, Liu W, Dong F, Huo Y, Zou R, Wang C, Zhang S, Liu W, Sun G, Lin L, Zeng K, Dong X, Guo Q, Yi F, Wang Z, Li X, Jiang B, Cao L, Zhao Y
Cell death & disease 2022 Apr 15;13(4):352

PRPF6 promotes androgen receptor/androgen receptor-variant 7 actions in castration-resistant prostate cancer cells.

Liu W, Wang C, Wang S, Zeng K, Wei S, Sun N, Sun G, Wang M, Zou R, Liu W, Lin L, Song H, Jin Z, Zhao Y
International journal of biological sciences 2021;17(1):188-203

ACSS3 represses prostate cancer progression through downregulating lipid droplet-associated protein PLIN3.

Zhou L, Song Z, Hu J, Liu L, Hou Y, Zhang X, Yang X, Chen K
Theranostics 2021;11(2):841-860

Melatonin inhibits lipid accumulation to repress prostate cancer progression by mediating the epigenetic modification of CES1.

Zhou L, Zhang C, Yang X, Liu L, Hu J, Hou Y, Tao H, Sugimura H, Chen Z, Wang L, Chen K
Clinical and translational medicine 2021 Jun;11(6):e449

KAT2A-mediated AR translocation into nucleus promotes abiraterone-resistance in castration-resistant prostate cancer.

Lu D, Song Y, Yu Y, Wang D, Liu B, Chen L, Li X, Li Y, Cheng L, Lv F, Zhang P, Xing Y
Cell death & disease 2021 Aug 12;12(8):787

A feedback loop between the androgen receptor and 6-phosphogluoconate dehydrogenase (6PGD) drives prostate cancer growth.

Gillis JL, Hinneh JA, Ryan NK, Irani S, Moldovan M, Quek LE, Shrestha RK, Hanson AR, Xie J, Hoy AJ, Holst J, Centenera MM, Mills IG, Lynn DJ, Selth LA, Butler LM
eLife 2021 Aug 12;10

KLF5 Is Crucial for Androgen-AR Signaling to Transactivate Genes and Promote Cell Proliferation in Prostate Cancer Cells.

Li J, Zhang B, Liu M, Fu X, Ci X, A J, Fu C, Dong G, Wu R, Zhang Z, Fu L, Dong JT
Cancers 2020 Mar 21;12(3)

Identification of reciprocal microRNA-mRNA pairs associated with metastatic potential disparities in human prostate cancer cells and signaling pathway analysis.

Ma H, Wang LY, Yang RH, Zhou Y, Zhou P, Kong L
Journal of cellular biochemistry 2019 Oct;120(10):17779-17790

TROAP regulates prostate cancer progression via the WNT3/survivin signalling pathways.

Ye J, Chu C, Chen M, Shi Z, Gan S, Qu F, Pan X, Yang Q, Tian Y, Wang L, Yang W, Cui X
Oncology reports 2019 Feb;41(2):1169-1179

Wnt5a induces and maintains prostate cancer cells dormancy in bone.

Ren D, Dai Y, Yang Q, Zhang X, Guo W, Ye L, Huang S, Chen X, Lai Y, Du H, Lin C, Peng X, Song L
The Journal of experimental medicine 2019 Feb 4;216(2):428-449

The Combination of Metformin and Valproic Acid Induces Synergistic Apoptosis in the Presence of p53 and Androgen Signaling in Prostate Cancer.

Tran LNK, Kichenadasse G, Butler LM, Centenera MM, Morel KL, Ormsby RJ, Michael MZ, Lower KM, Sykes PJ
Molecular cancer therapeutics 2017 Dec;16(12):2689-2700

No comments: Submit comment

Supportive validation

Submitted by: Proteintech Group (provider)
Main image
Experimental details: Immunohistochemical of paraffin-embedded human prostate cancer using 10679-1-AP(KLK3,PSA antibody) at dilution of 1:50 (under 10x lens)
Sample type: tissue

Supportive validation

Submitted by: Proteintech Group (provider)
Main image
Experimental details: The KLK3/PSA antibody from Proteintech is a rabbit polyclonal antibody to a recombinant protein of human KLK3/PSA. This antibody recognizes human antigen. The KLK3/PSA antibody has been validated for the following applications: ELISA, IHC analysis.
Appendix: 10679-1-AP.pdf

: Show more